MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

GlobeNewsWire • Feb 17, 2026

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

Agreement expands offering to include additional sheet, particulate and flowable products Agreement expands offering to include additional sheet, particulate and flowable products

GlobeNewsWire • Feb 4, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications

GlobeNewsWire • Feb 2, 2026

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.

GlobeNewsWire • Dec 22, 2025

MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, MiMedx Group, Inc (MDXG) is looking like an interesting pick, as it just reached a key level of support. MDXG's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks Investment Research • Nov 17, 2025

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

GlobeNewsWire • Nov 13, 2025

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16 th Annual Alpha Select Conference | New York, NY Tuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY Thursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum or Canaccord representative.

GlobeNewsWire • Nov 10, 2025

MiMedx: Breakout Setup Into A Policy Overhaul

MiMedx Group is positioned for growth, with strong earnings, record Q3 revenue, and a rising contribution from its Surgical business. MDXG is proactively managing 2026 reimbursement policy risks by shifting product mix, accepting near-term price pressure, and leveraging its MiMedx Connect platform. Valuation analysis suggests MDXG is undervalued by ~20%, with feasible revenue growth and FCF margin assumptions supported by recent financial performance.

Seeking Alpha • Nov 4, 2025

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday.

GlobeNewsWire • Nov 3, 2025

Wall Street Analysts Predict a 64.86% Upside in MiMedx (MDXG): Here's What You Should Know

The mean of analysts' price targets for MiMedx (MDXG) points to a 64.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Oct 31, 2025